Compare the documented conditions, not an unsupported winner. Base is the shared deployment in this comparison; fee evidence is incomplete and no comparable live execution tests have been performed.
Reviewed 2026-10-22Version 1.1.0No live execution tests
A separate 15 October source-access follow-up adds retrieved detail pages and flags fee inconsistencies. The original snapshot below is preserved.
What Matters
Compare like with like. Keep the gaps visible.
Comparison compiled on 22 October from gTrade 1.1.0 and the unchanged Veranta 1.0.0 snapshot. Veranta was not fully re-reviewed; its 28 October deadline remains controlling. No live quote, execution test or ranking.
The shared network is Base and the documented collateral overlap is USDC. There is no blended score or cheapest-platform claim. Documentation coverage differs; that does not establish a difference in safety.
USDC is a documented overlap. Other networks or token funding routes are outside this shared-deployment lens.
Trace related claims
These dated claims provide context for this row. Each may cover only part of the comparison. Open a claim to inspect its evidence trail or save it in your browser.
The current documentation permits closing existing DAI positions but no new DAI trades on Arbitrum or Polygon. It does not measure collateral usage shares.
No cheapest-venue conclusion. Compare the same asset, mode, size, direction, time and holding period before measuring costs.
Trace related claims
These dated claims provide context for this row. Each may cover only part of the comparison. Open a claim to inspect its evidence trail or save it in your browser.
The overview describes zero maker/taker fees for RWAs while in growth mode, alongside spreads and carry. Upside Perps, previously ZFP, take fees from profits.
Neither platform receives a fill-quality, latency or stop-loss score.
Trace related claims
These dated claims provide context for this row. Each may cover only part of the comparison. Open a claim to inspect its evidence trail or save it in your browser.
gTrade
Underlying review: 2026-10-22 · brief v1.1.0
No individual claim is mapped for this part of the comparison. This does not establish that the condition is safe, available or unchanged.
Do not infer comparable security from wallet-based access or gas sponsorship.
Trace related claims
These dated claims provide context for this row. Each may cover only part of the comparison. Open a claim to inspect its evidence trail or save it in your browser.
gTrade
Underlying review: 2026-10-22 · brief v1.1.0
No individual claim is mapped for this part of the comparison. This does not establish that the condition is safe, available or unchanged.
The overview advertises gasless one-click execution. DN did not inspect a live approval flow or verify the scope, duration and revocation of any delegated permissions.
Evidence coverage is asymmetric. An unknown is not permission to use a platform.
Trace related claims
These dated claims provide context for this row. Each may cover only part of the comparison. Open a claim to inspect its evidence trail or save it in your browser.
Individual eligibility and safe permission settings
No numerical all-in cost is calculated. A valid comparison needs contemporaneous quotes for matching assets, product modes, notional sizes, directions and holding periods, with entry, holding and exit costs included.
Your research record
Keep the evidence. Keep its limits.
The receipt preserves all underlying evidence snapshots and the comparison at version 1.1.0.
Pinned gTrade 1.1.0. Base collateral overlap is unchanged. Veranta 1.0.0 and its source-access follow-up retain their original dates; no complete Veranta refresh is claimed.
DN publication
Initial comparison pinned to gTrade 1.0.0 and Veranta 1.0.0. Provider claims and DN measurement gaps remain separate.
Review triggers: Either underlying brief receives a new version; Changed documentation or substantiated correction; The earliest underlying review deadline. No automated provider surveillance runs for this brief.
How to use this research
Provider-reported describes the source of a statement, not an independent endorsement. Unknown and not measured identify evidence gaps. A documentation review does not confer an operational-status classification or establish user eligibility.
DN has referral relationships or entries for these platforms. This comparison has no partner CTAs, payout-based ordering or overall winner.
Educational research only, not investment, legal or tax advice. Leveraged derivatives can cause substantial losses.
